Murali Ramachandran — SEC Form 4 filings
SEC reporting owner CIK 1870016. 3 Form 4 filings on record with FilingPulse; latest filed 2025-11-26.
Transaction summary — filings shown
Covers all 3 filings on record, filed 2024-11-25 to 2025-11-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 200 shares, $318 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: purchase of 200 shares @ $1.59 ($318) in Kairos Pharma, LTD., filed 2024-11-25.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | VP of Research and Development | 3 | 1 leg · 200 sh · $318 | — | 2 |
Form 4 filings — Murali Ramachandran
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-11-26 | 4 | Kairos Pharma, LTD. (KAPA) | Grant/award (A): 152,672 @ $0 | EDGAR |
| 2025-02-24 | 4 | Kairos Pharma, LTD. (KAPA) | Grant/award (A): 14,000 @ $0 | EDGAR |
| 2024-11-25 | 4 | Kairos Pharma, LTD. (KAPA) | Purchase (P): 200 @ $1.59 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1870016 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →